- Home
- GRVY vs BIOA Comparison
GRVY vs BIOA Comparison
Compare GRVY & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | BIOA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.5M | 481.0M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GRVY | BIOA |
|---|---|---|
| Price | $71.19 | $9.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 40.8K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | N/A | $720.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.54 | $4.55 |
| 52 Week High | $74.75 | $25.96 |
Technical Indicators
Market Signals| Indicator | GRVY | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 66.30 | 29.57 |
| Support Level | $60.50 | $8.56 |
| Resistance Level | $71.94 | $11.94 |
| Average True Range (ATR) | 2.48 | 0.66 |
| MACD | 0.39 | 0.04 |
| Stochastic Oscillator | 99.01 | 8.27 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. The gaming products of the company include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation. Geographically, it derives maximum revenue from Taiwan.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.